(Q32019400)

5 July 2017

Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis (English)

1 reference

5 July 2017

1 reference

1 reference

C H Banov

1

1 reference

5 July 2017

P Lieberman

series ordinal

2

1 reference

5 July 2017

Vasomotor Rhinitis Study Groups

series ordinal

3

1 reference

5 July 2017

language of work or name

1 reference

1 January 2001

1 reference

Annals of Allergy, Asthma & Immunology

5 July 2017

1 reference

5 July 2017

86

1 reference

5 July 2017

1

1 reference

5 July 2017

28-35

1 reference

Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology

5 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Management of allergic rhinitis with a combination antihistamine/anti-inflammatory agent

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Inhibition of leukotriene synthesis by azelastine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

The effect of azelastine on neutrophil and eosinophil generation of superoxide

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

The use of intranasal anticholinergic agents in the treatment of nonallergic perennial rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Neuropeptides in nasal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Substance P and neurokinin A in human nasal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Neuropeptides and nasal secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Do nasal mast cells release histamine on stimulation with substance P in allergic rhinitis?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Effects of anti-allergic drugs on substance P (SP) and vasoactive intestinal peptide (VIP) in nasal secretions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Tryptase and histamine as markers to evaluate mast cell activation during the responses to nasal challenge with allergen, cold, dry air, and hyperosmolar solutions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Nasal challenge with cold, dry air induces a late-phase reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Inhibitory effects of azelastine hydrochloride in alcohol-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Effect of azelastine on leukotriene synthesis in murine peritoneal cells and on thromboxane synthesis in human platelets

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Effect of azelastine on the release and action of leukotriene C4 and D4.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Inhibitory effects of various drugs on phorbol myristate acetate and n-formyl methionyl leucyl phenylalanine induced O2- production in polymorphonuclear leukocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Effects of anti-allergic drugs on human neutrophil superoxide-generating NADPH oxidase

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

The effect of azelastine on the early allergic response

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

Molecular mechanisms of steroid action in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962352-6

7 January 2021

10.1016/S1081-1206(10)62352-6

Identifiers

DOI

1 reference

5 July 2017

1 reference